Monitoring Long-Term Efficacy of Migraine Wearable Device Over 3 Years: Alit Stark-Inbar, PhD

WATCH TIME: 5 minutes | Captions are auto-generated and may contain errors.

"The goal of this study was to track patients over a long period of time. We looked at patients who treated their migraine disease with Nerivio for over 3 years, a very long time in the space of migraine. There are a few long-term studies that go over a year, but I don't know of any other studies that track patients for 3 years on a month-by-month basis, collecting prospective data."

Theranica recently presented new data of its FDA-cleared Nerivio remote electrical neuromodulation (REN) wearable device, indicated for both acute and preventive treatment of migraine in patients aged 8 years and older, at the 2025 American Headache Society (AHS) Annual Meeting, held June 19-22 in Minneapolis, Minnesota. In a long-term study, results demonstrated that the REN wearable maintained consistent efficacy for migraine treatment over 3 years, with no signs of tachyphylaxis. During the study, patients reported consistent pain relief, functional recovery, and freedom from migraine-associated symptoms.^1,2

An additional study presented at AHS 2025 compared the impact of REN for the treatment of migraine with and without aura in a cohort of nearly 32,000 patients. Although patients with aura started with more severe baseline symptoms, their treatment outcomes were similar to, and in some cases slightly better than, those without aura. Both groups also showed improvements in pain relief, functional recovery, and resolution of migraine-related symptoms. Overall, these recently presented data from Theranica supported the REN wearable device as a nondrug alternative option for patients with migraine, showing efficacy in both acute and preventive migraine.

Following the presentations held at AHS 2025, coauthor Alit Stark-Inbar, PhD, corporate vice president of medical information and research at Theranica, sat down with NeurologyLive^® to offer more details on the 3-year, real-world findings assessing the REN wearable device Nerivio in both acute and preventive migraine treatment. In the interview, Stark-Inbar highlighted that the study prospectively tracked patients using the device monthly, collecting real-time efficacy and usage data. She noted that the key outcomes included sustained treatment efficacy without the need for increased intensity, suggesting no evidence of tachyphylaxis, and stable treatment patterns over time. Furthemore, Stark-Inbar explained that the long-term data adds value to support the viability of Nerivio as a durable nonpharmacologic option in migraine care.

Click here for more coverage of AHS 2025.

REFERENCES
1. Nahas SJ, Birlea M, Stark-Inbar A, et al. Remote Electrical Neuromodulation (REN) Shows Consistent Efficacy without Tachyphylaxis Over Three Years of Treatment. Presented at: 2025 AHS Annual Meeting; June 19-22; Minneapolis, MN.
2. Theranica to Present Three Real-World Evidence Studies at AHS Scientific Meeting Highlighting the Impact of the Nerivio® REN Wearable on Migraine Treatment. News Release. Theranica. Published June 19, 2025. Accessed August 6, 2025. https://www.nerivio.com/news-press/theranica-to-present-three-real-world-evidence-studies-at-ahs-scientific-meeting-highlighting-the-impact-of-the-nerivio-r-ren-wearable-on-migraine-treatment

Editor’s Note: Graphics in this video were provided by Theranica.